Sonoma Pharmaceuticals (SNOA) awards 10,000 stock options to director Vanessa Jacoby

Rhea-AI Filing Summary

Sonoma Pharmaceuticals director Vanessa Jacoby received a grant of stock options. She was awarded options to acquire 10,000 shares of common stock at an exercise price of $1.26 per share for Board service. The options vest one-third each on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control, and expire on July 9, 2036. Following this grant, she holds 20,000 derivative option shares in total.

Insights

Equity compensation analyst

Routine director option grant expands equity-based compensation.

Director Vanessa Jacoby was granted stock options for 10,000 shares of common stock at an exercise price of $1.26 per share. This is classified as a grant or award acquisition, not an open-market purchase or sale.

The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control, creating a multi-year incentive to remain on the Board. After the award, she holds options over 20,000 shares, indicating this grant approximately doubled her reported derivative holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jacoby Vanessa

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control. The options were awarded and granted to Ms. Jacoby for services performed on the Board of Directors.

Key Figures

Options granted: 10,000 shares Exercise price: $1.26 per share Post-grant option holdings: 20,000 shares +2 more

5 metrics

Options granted 10,000 shares Stock option (right to buy) grant to director Vanessa Jacoby

Exercise price $1.26 per share Conversion or exercise price of granted stock options

Post-grant option holdings 20,000 shares Total derivative option shares held following the transaction

Expiration date July 9, 2036 Expiration of stock options granted to Vanessa Jacoby

Vesting dates July 9, 2027; July 9, 2028; July 9, 2029 Options vest one-third on each of these dates or upon change of control

Key Terms

Stock option (right to buy), exercise price, change of control

3 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change of control financial

"vest one third each ... or upon change of control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 08:47 PM Accepted by SEC EDGAR 07/09/2026 - 08:47 PM Learn about SEC filing dates

FAQ

What did Sonoma Pharmaceuticals (SNOA) director Vanessa Jacoby report in this Form 4?

Director Vanessa Jacoby reported receiving a grant of stock options for 10,000 shares of Sonoma Pharmaceuticals common stock. The options are compensation for Board service and are not an open-market transaction.

What is the exercise price of the options granted to Vanessa Jacoby at SNOA?

The options granted to Vanessa Jacoby have an exercise price of $1.26 per share. This is the price she must pay to acquire each share if she exercises the options in the future.

How and when do Vanessa Jacoby’s Sonoma Pharmaceuticals options vest?

The options vest in three equal installments: one-third on July 9, 2027, one-third on July 9, 2028, and one-third on July 9, 2029, or earlier upon a change of control.

When do the stock options granted to Vanessa Jacoby at SNOA expire?

The stock options granted to Vanessa Jacoby expire on July 9, 2036. After that expiration date, any unexercised options will no longer be exercisable for Sonoma Pharmaceuticals common stock.

What are Vanessa Jacoby’s total reported option holdings in Sonoma Pharmaceuticals after this grant?

Following the grant, Vanessa Jacoby holds 20,000 derivative option shares in total. The new award added 10,000 options to her existing position, as reflected in the post-transaction holdings field.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacoby Vanessa

(Last) (First) (Middle)

C/O SONOMA PHARMACEUTICALS, INC.

5445 CONESTOGA COURT, SUITE 150

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sonoma Pharmaceuticals, Inc. [ SNOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.26	07/09/2026		A		10,000		(1)	07/09/2036	Common Stock	10,000	(2)	20,000	D

Explanation of Responses:

1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.

2. The options were awarded and granted to Ms. Jacoby for services performed on the Board of Directors.

	/s/ Amy Trombly as attorney-in-fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)